How Long Should I Stay on 2.5mg Mounjaro?

2.5mg is tirzepatide's tolerability dose (its job is to let your system adjust, not to deliver the full weight-management effect
The licensed schedule moves most people up after four weeks, but your prescriber can extend that period if side effects need more time to settle
Staying on 2.5mg longer than intended is not harmful, but it does delay reaching the dose where clinical results are most pronounced
Any dose change requires a clinical re-review) at nume, every repeat order is assessed by a GPhC-registered Independent Prescriber before dispatch

The 2.5mg dose of Mounjaro is designed as a four-week starter, not a long-term treatment dose. Most people move on after one pen. But how long you stay on 2.5mg Mounjaro depends on how your body settles in during those first weeks — and that decision belongs to your prescriber, not a timer. Mounjaro (tirzepatide) is a prescription-only medicine, so any change to your dose is made clinically, based on your individual response.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the 2.5mg period is actually for, and when it ends

Why does Mounjaro start at 2.5mg at all?

Tirzepatide activates two gut-hormone receptors simultaneously (GIP and GLP-1) which is what makes it distinct from other weight-loss medicines. That dual action is also why the body can take a little time to adjust. Starting at a lower dose means the nausea, indigestion and fatigue that some people notice are far less likely to derail treatment in the first few weeks.

So 2.5mg is not a therapeutic dose in the way that 10mg or 15mg is. The first pen's job is adjustment. You are not expected to see significant weight loss at 2.5mg, and if you notice very little happening, that is by design. The NHS tirzepatide medicines page describes this clearly: the dose is titrated upwards as tolerability is established.

That framing matters if you are feeling impatient four weeks in. The starter dose is doing something — it is just doing it quietly, getting your gut used to a mechanism it has never encountered before. Most people find the therapeutic benefit becomes clearer once they have moved through a couple of dose steps.

How long should you stay on 2.5mg Mounjaro before going up?

The licensed schedule, as described in the Mounjaro SmPC, is four weeks at each dose level. For the vast majority of people, one four-week pen at 2.5mg is the plan, followed by a move to 5mg. If you ordered on a Monday in the middle of the month, your next order and clinical review would typically fall around the same time the following month, timing can be useful to plan around a payday or a holiday, since you will want your pen in the fridge before you travel.

That said, your prescriber may advise staying on 2.5mg for an additional four weeks if side effects have been particularly troublesome and have not yet settled. This is not unusual. The guidance from NICE's appraisal of tirzepatide (TA1026) supports flexibility in titration to balance tolerability against progress. What the guidance does not support is staying at 2.5mg indefinitely if it is well tolerated, because the medicine's weight-management evidence base is built on reaching higher maintenance doses.

If you are wondering whether to push through to 5mg or sit tight, our page on whether to stay on 2.5mg Mounjaro covers the specific factors worth considering before your next review.

What happens if you stay on 2.5mg longer than planned?

Remaining on 2.5mg for eight or twelve weeks rather than four is not dangerous. The medicine is the same compound; the dose is simply lower than where it needs to be for most people's treatment goals. The practical consequence is that weight loss is likely to be minimal during that extended period, which can feel disheartening when you are trying to judge whether treatment is working.

There is also a secondary consideration. If treatment is extended at 2.5mg without a clinical reason, it may affect the timeline for reaching a dose where the published evidence (including the SURMOUNT-1 trial, in which average weight reduction reached around 20–21% at the highest doses) begins to apply to your situation. The dose you are on now is not the dose those results were measured at.

For people thinking through the 5mg transition specifically, our guide on how long to stay on 5mg Mounjaro picks up the question at that next stage. And if you are preparing for your very first injection, practical tips for your first Mounjaro dose covers the things it helps to know before you start.

Who decides when 2.5mg becomes 5mg?

Your prescriber. Not you, not a generic schedule printed on a box. This is not a formality, it is a genuine clinical assessment of how your body responded during the starter phase, what side effects you experienced, and whether there is any reason to delay titration. At nume, every repeat order goes through this re-review before anything is dispatched. A real clinician reads your responses; nothing is automated.

That matters particularly because some people arrive at the 5mg decision having had a rougher first four weeks than they expected. Others feel fine and want to move quickly. Both are valid data points for a prescriber to work with. If you have questions about how long you stay on 2.5mg Mounjaro before that transition, a short message through our support team can get your question in front of the right person before your next order is due.

You can read more about how our clinical team approaches these decisions on our prescriber profile page, or explore the broader picture of Mounjaro as a weight-management medicine if you are still building your understanding of tirzepatide. For people weighing up whether the move to 5mg is right for them, our page on whether to stay on 5mg Mounjaro sets out the key considerations in one place. For a broader look at all available weight-loss treatments, our treatment overview is a useful starting point.

When you are ready to have the dose conversation properly, speak to our prescribers through a free consultation, no waiting list, reviewed the same day.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions